These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17557136)

  • 1. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
    Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
    J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
    J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
    Church DN; Bahl A; Jones A; Price CG
    J Neurooncol; 2006 Sep; 79(3):289-92. PubMed ID: 16821088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.
    Xiao C; Gong Y; Han EY; Gonzalez-Angulo AM; Sneige N
    Ann Oncol; 2011 Jul; 22(7):1547-1553. PubMed ID: 21239403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
    Niwińska A; Tacikowska M; Murawska M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
    Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
    Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
    Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
    Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
    Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
    Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
    Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
    Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.
    Bartsch R; De Vries C; Pluschnig U; Dubsky P; Bago-Horvath Z; Gampenrieder SP; Rudas M; Mader RM; Rottenfusser A; Wiltschke C; Gnant M; Zielinski CC; Steger GG
    BMC Cancer; 2009 Oct; 9():367. PubMed ID: 19835621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.